

# Konstantin Doberer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6241337/publications.pdf>

Version: 2024-02-01

27  
papers

744  
citations

840776

11  
h-index

752698

20  
g-index

27  
all docs

27  
docs citations

27  
times ranked

929  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients. <i>JAMA Internal Medicine</i> , 2022, 182, 165.	5.1	100
2	Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. <i>Trials</i> , 2022, 23, 270.	1.6	8
3	Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection. <i>Frontiers in Medicine</i> , 2022, 9, 817127.	2.6	2
4	Proteinuria in Deceased Kidney Transplant Donors for Prediction of Chronic Lesions in Pretransplant Biopsies: A Prospective Observational Study. <i>Transplantation</i> , 2022, Publish Ahead of Print, .	1.0	2
5	MO1022: Torque Teno Virus Load in Kidney Transplantation: Association with Donor and Recipient Characteristics and Clinical Follow-Up Data. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
6	MO1023: Effects of Bortezomib on Complement Fixation and IGM Reactivity in Late Abmr " Results of A Randomized Controlled Trial (The Borteject Trial). <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
7	Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 151-167.	2.4	13
8	Determinants of the intercept and slope of glomerular filtration rate in recipients of a live donor kidney transplant. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 107-117.	1.9	1
9	A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 708-722.	6.1	101
10	CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. <i>Transplantation</i> , 2021, 105, 451-457.	1.0	57
11	Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. <i>Transplant International</i> , 2021, 34, 1542-1552.	1.6	7
12	Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients. <i>Transplant International</i> , 2021, 34, 1689-1702.	1.6	16
13	Torque Teno Virus Load Is Associated With Subclinical Alloreactivity in Kidney Transplant Recipients: A Prospective Observational Trial. <i>Transplantation</i> , 2021, 105, 2112-2118.	1.0	29
14	New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 97-105.	1.6	11
15	P1624TORQUE TENO VIRUS FOR RISK STRATIFICATION OF GRAFT REJECTION AND INFECTION IN KIDNEY TRANSPLANT RECIPIENTS - A PROSPECTIVE OBSERVATIONAL TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	1
16	P1643TORQUE TENO VIRUS FOR RISK STRATIFICATION OF SUBCLINICAL GRAFT REJECTION AFTER KIDNEY TRANSPLANTATION- A PROSPECTIVE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
17	An author's reply to the editorial "Torque Teno virus load as a surrogate marker for the net state of immunosuppression: The beneficial side of the virome". <i>American Journal of Transplantation</i> , 2020, 20, 2280-2281.	4.7	0
18	Immunoabsorption Combined with Membrane Filtration to Counteract Early Treatment-Refractory Antibody-Mediated Rejection. <i>Blood Purification</i> , 2020, 49, 576-585.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipientsâ€™ A prospective observational trial. American Journal of Transplantation, 2020, 20, 2081-2090.	4.7	64
20	High-activity Classical and Alternative Complement Pathway Genotypesâ€™ Association With Donor-specific Antibody-triggered Injury and Renal Allograft Survival. Transplantation Direct, 2020, 6, e534.	1.6	1
21	Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients. Frontiers in Medicine, 2020, 7, 114.	2.6	20
22	Torque Teno Virus for Risk Stratification of Acute Biopsy-Proven Alloreactivity in Kidney Transplant Recipients. Journal of Infectious Diseases, 2019, 219, 1934-1939.	4.0	46
23	The therapeutic challenge of late antibody-mediated kidney allograft rejection. Transplant International, 2019, 32, 775-788.	1.6	89
24	Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials, 2019, 20, 37.	1.6	48
25	Quantification of Torque Teno Virus Viremia as a Prospective Biomarker for Infectious Disease in Kidney Allograft Recipients. Journal of Infectious Diseases, 2018, 218, 1191-1199.	4.0	93
26	Longitudinal assessment of HLA and MIC-A antibodies in uneventful pregnancies and pregnancies complicated by preeclampsia or gestational diabetes. Scientific Reports, 2017, 7, 13524.	3.3	8
27	PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically Quiescent. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1913-1922.	2.4	22